A law of nature dictates that high complexity and high precision are mutually exclusive. This places a physical limit on the precision AI can achieve in complex fields like biology. Pushing models for more precision in these areas leads to diminishing returns, plateaus, and hallucinations as they fight against this fundamental principle.
A BMW project to optimize airbag deployment with neural nets worked perfectly but taught the engineers nothing about the underlying physics. The model was a black box of coefficients. This highlights AI's limitation: it can provide a solution for one problem but fails to generate new, generalizable knowledge.
Conventional molecular complexity metrics fail because they treat molecules as static objects. In reality, a molecule's properties like solubility or bioactivity are emergent from its dynamic motion, which changes based on its environment (e.g., temperature, solvents), much like a stock's behavior changes across different markets.
By analyzing information flow, Quantitative Complexity Theory (QCT) pinpoints 'hotspots'—the specific atoms or amino acids that dominate a molecule's dynamics. These hotspots, which carry the largest information footprint, essentially direct the biological 'orchestra.' They provide medicinal chemists with precise targets for re-engineering a molecule's function.
Protein folding isn't just about finding the most stable, lowest-energy state. It's a dual optimization process where nature also maximizes the molecule's complexity to encode the maximum possible amount of functional information. This ensures the structure is both stable and information-rich, achieving two goals simultaneously.
When all pharma companies use similar AI models on similar data, competitive moats vanish. The next edge will come from creating superior training data. This means moving beyond raw data to datasets enriched with physical insights, such as a database of 'complexity hotspots' for all known proteins, teaching AI the underlying dynamics.